PT2293819E - Método para diagnosticar cancros que expressam o recetor her2 ou as suas variantes truncadas - Google Patents

Método para diagnosticar cancros que expressam o recetor her2 ou as suas variantes truncadas Download PDF

Info

Publication number
PT2293819E
PT2293819E PT97722656T PT09772265T PT2293819E PT 2293819 E PT2293819 E PT 2293819E PT 97722656 T PT97722656 T PT 97722656T PT 09772265 T PT09772265 T PT 09772265T PT 2293819 E PT2293819 E PT 2293819E
Authority
PT
Portugal
Prior art keywords
her2 receptor
receptor variant
cancers expressing
diagnosing cancers
truncated her2
Prior art date
Application number
PT97722656T
Other languages
English (en)
Inventor
Joaquín Arribas López
Kim Pedersen
Pier-Davide Angellini
Josep Lluis Parra Palau
Sirle Laos
José Baselga Torres
Original Assignee
Fundació Privada Inst De Recerca Hospital Uni Vall Hebron
Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Fundació Privada Inst D Investigació Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Inst De Recerca Hospital Uni Vall Hebron, Fundació Privada Institució Catalana De Recerca I Estudis Avancats, Fundació Privada Inst D Investigació Oncologica De Vall Hebron filed Critical Fundació Privada Inst De Recerca Hospital Uni Vall Hebron
Publication of PT2293819E publication Critical patent/PT2293819E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
PT97722656T 2008-06-02 2009-06-05 Método para diagnosticar cancros que expressam o recetor her2 ou as suas variantes truncadas PT2293819E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.

Publications (1)

Publication Number Publication Date
PT2293819E true PT2293819E (pt) 2014-12-09

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97722656T PT2293819E (pt) 2008-06-02 2009-06-05 Método para diagnosticar cancros que expressam o recetor her2 ou as suas variantes truncadas

Country Status (21)

Country Link
US (1) US8389227B2 (pt)
EP (1) EP2293819B1 (pt)
JP (2) JP5753079B2 (pt)
KR (2) KR101785117B1 (pt)
CN (1) CN102202692B (pt)
AU (2) AU2009265921B2 (pt)
BR (1) BRPI0914969A2 (pt)
CA (1) CA2727365A1 (pt)
CY (1) CY1115798T1 (pt)
DK (1) DK2293819T3 (pt)
EA (1) EA025218B1 (pt)
ES (2) ES2342646B1 (pt)
HK (1) HK1157658A1 (pt)
HR (1) HRP20141158T1 (pt)
IL (1) IL209769A (pt)
MX (1) MX2010013419A (pt)
PL (1) PL2293819T3 (pt)
PT (1) PT2293819E (pt)
SI (1) SI2293819T1 (pt)
WO (1) WO2010000565A1 (pt)
ZA (1) ZA201009010B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638598B2 (en) * 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
NZ616755A (en) * 2009-05-14 2015-05-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
SI2330131T1 (sl) * 2009-12-07 2015-02-27 Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants Protitelesa proti HER2 skrajšani varianti CTF-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
RS62143B1 (sr) 2014-03-11 2021-08-31 Molecular Templates Inc Proteini koji uključuju podjedinice proksimalnih aminoterminalnih efektorskih regiona šiga toksina i vezni regioni imunoglobulinskog tipa koji ciljaju ćelije sposobni da specifično vezuju cd38
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
EP3455260B1 (en) 2016-05-12 2022-07-06 Agency for Science, Technology and Research Anti-erbb-2 antibodies and uses thereof
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
EP4003407A1 (en) 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE69535673D1 (de) 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
DK1210115T3 (da) * 1999-08-27 2009-11-30 Genentech Inc Doseringer til behandling med anti-ErB2-antistoffer
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95

Also Published As

Publication number Publication date
JP2015214546A (ja) 2015-12-03
US8389227B2 (en) 2013-03-05
CN102202692B (zh) 2014-03-12
KR20110031187A (ko) 2011-03-24
ES2528132T3 (es) 2015-02-04
EP2293819A1 (en) 2011-03-16
ZA201009010B (en) 2012-03-28
ES2342646B1 (es) 2011-04-26
JP2011525175A (ja) 2011-09-15
AU2009265921B2 (en) 2015-04-02
MX2010013419A (es) 2011-08-15
KR20160140974A (ko) 2016-12-07
EA201001874A1 (ru) 2011-08-30
EP2293819B1 (en) 2014-09-03
IL209769A (en) 2016-04-21
AU2009265921A1 (en) 2010-01-07
DK2293819T3 (en) 2014-12-08
IL209769A0 (en) 2011-02-28
WO2010000565A1 (en) 2010-01-07
US20090311262A1 (en) 2009-12-17
ES2342646A1 (es) 2010-07-09
KR101785117B1 (ko) 2017-11-07
CA2727365A1 (en) 2010-01-07
EA025218B1 (ru) 2016-12-30
AU2015202854A1 (en) 2015-06-18
JP5753079B2 (ja) 2015-07-22
PL2293819T3 (pl) 2015-04-30
CY1115798T1 (el) 2017-01-25
CN102202692A (zh) 2011-09-28
BRPI0914969A2 (pt) 2015-10-20
HK1157658A1 (en) 2012-07-06
HRP20141158T1 (hr) 2015-02-13
SI2293819T1 (sl) 2015-01-30

Similar Documents

Publication Publication Date Title
PL2293819T3 (pl) Sposób diagnozowania raków z ekspresją skróconego wariantu receptora Her2
HK1163935A1 (en) Method for making via interconnection
HK1164811A1 (en) Atv having arrangement for a passenger
EP2244908A4 (en) HEADREST FOR CARS
IL208392A (en) Estrogen receptor ligands
EP2341449A4 (en) METHOD FOR OBTAINING INFORMATION ASSOCIATED WITH A LOCATION
HK1133283A1 (zh) 種癌症篩檢的方法
HRP20141257T1 (en) Antibodies against her2 truncated variant ctf-611
ZA201103178B (en) Anti-tgf-beta receptor ii antibodies
EP2401162A4 (en) METHOD OF USE OF VOID PANTOGRAPHS
IL215669A0 (en) A method for screening cancer
HK1133231A1 (en) Method for producing a multi-layered object
IL211424A0 (en) Method for diagnostic marker development
EP2296469A4 (en) KAPPA OPIOID RECEPTOR LIGANDS
GB0806656D0 (en) Novel estrogen receptor ligands
EP2364963A4 (en) PROCESS AND PREPARATION OF OLEFIN
HK1151764A1 (en) Recess filling apparatus
GB0817221D0 (en) Novel estrogen receptor ligands
GB0806657D0 (en) Novel estrogen receptor ligands
GB0806074D0 (en) Novel estrogen receptor ligands
ZA201005707B (en) Method for mining
HK1129991A2 (en) A forming method for three-colour-scissors
TWI346613B (en) A method for forming a structure
GB0919939D0 (en) Apparatus for extending accomodation within a vehicle
EP2377657A4 (en) METHOD FOR OBTAINING A PART MADE FROM A FIRE-RESISTANT MATERIAL